Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

ABSTRACT:

Background

Selective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.

Methods

A systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn's disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases were searched for real-world studies of vedolizumab in adult patients with UC/CD reporting clinical response, remission, corticosteroid-free remission, UC/CD-related surgery or hospitalization, mucosal healing, or safety published from May 1, 2014-June 22, 2017. Response and remission rates were combined in random-effects meta-analyses.

Results

At treatment week 14, 32% of UC patients [95% c

SUBMITTER: Schreiber S 

PROVIDER: S-EPMC6132930 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature